These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 34021874)

  • 1. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Javidi-Sharifi N; Brown JR
    Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
    St-Pierre F; Ma S
    Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
    Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
    N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Suzumiya J; Takizawa J
    Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
    Gu D; Li J; Miao Y
    Expert Opin Pharmacother; 2022 Dec; 23(18):1979-1986. PubMed ID: 36329558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
    Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
    Bennett R; Seymour JF
    Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline Therapy of CLL: Evolving Treatment Paradigm.
    Boddy CS; Ma S
    Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
    Siddiqi T
    Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Markers in the Era of Targeted Therapies.
    Kang S; Ahn IE
    Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
    Rainone M; Siddiqi T
    Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.